Remogliflozin etabonate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Remogliflozin etabonate
Accession Number
DB12935
Description

Remogliflozin etabonate has been used in trials studying the treatment and basic science of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 522.595
Monoisotopic: 522.257730812
Chemical Formula
C26H38N2O9
Synonyms
Not Available
External IDs
  • GSK-189075
  • GSK-189075A
  • GSK189075A

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Remogliflozin etabonate.
AcebutololThe therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Remogliflozin etabonate.
Acetyl sulfisoxazoleThe therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Remogliflozin etabonate.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with Remogliflozin etabonate.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with Remogliflozin etabonate.
AlogliptinThe risk or severity of hypoglycemia can be increased when Alogliptin is combined with Remogliflozin etabonate.
AmcinonideThe risk or severity of hyperglycemia can be increased when Amcinonide is combined with Remogliflozin etabonate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Oxanes / Monosaccharides / Carbonic acid diesters / Pyrazoles / Heteroaromatic compounds / Secondary alcohols / Polyols
show 8 more
Substituents
Acetal / Alcohol / Alkyl aryl ether / Aromatic heteromonocyclic compound / Azacycle / Azole / Benzenoid / Carbonic acid derivative / Carbonic acid diester / Carbonyl group
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
TR0QT6QSUL
CAS number
442201-24-3
InChI Key
UAOCLDQAQNNEAX-ABMICEGHSA-N
InChI
InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
IUPAC Name
ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-{[5-methyl-1-(propan-2-yl)-4-{[4-(propan-2-yloxy)phenyl]methyl}-1H-pyrazol-3-yl]oxy}oxan-2-yl]methyl carbonate
SMILES
CCOC(=O)OC[[email protected]]1O[[email protected]@H](OC2=NN(C(C)C)C(C)=C2CC2=CC=C(OC(C)C)C=C2)[[email protected]](O)[[email protected]@H](O)[[email protected]@H]1O

References

General References
Not Available
PubChem Compound
9871420
PubChem Substance
347829080
ChemSpider
8047110
ChEMBL
CHEMBL2028665
ZINC
ZINC000003979756
Wikipedia
Remogliflozin_etabonate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentType 1 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus4
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
1CompletedTreatmentImpaired kidney function / Type 2 Diabetes Mellitus1
1CompletedTreatmentType 2 Diabetes Mellitus10

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.189 mg/mLALOGPS
logP3.33ALOGPS
logP3.52ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)12.2ChemAxon
pKa (Strongest Basic)1.49ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area141.73 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity144.61 m3·mol-1ChemAxon
Polarizability55.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 19:25 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates